

Cuba reaches 20 million doses of Abdala vaccine produced in Cuba

Image not found or type unknown

Havana, August 14 (RHC)--Cuba's Biotechnological and Pharmaceutical Industries Business Group (CIGB) announced on Twitter that 20 million doses of the anti-COVID-19 Abdala vaccine had been produced.

The message points out that the scientific community, particularly the workers of AICA and CIGB laboratories, dedicate this productive milestone to the historical leader of the Revolution, Fidel Castro, 95 years after his birth.

Last July 9, the Cuban regulatory authority, the Center for State Control of Medicines, Equipment and Medical Devices (CECMED), authorized Abdala for emergency use, making it the first anti-SARS-CoV-2 vaccine developed and produced in Latin America and the Caribbean.

It was previously reported that in Phase III clinical trial, with its three-dose schedule, it had shown the efficacy of 92.28 percent in preventing symptomatic disease caused by the virus.

<https://www.radiohc.cu/en/noticias/nacionales/267007-cuba-reaches-20-million-doses-of-abdala-vaccine-produced-in-cuba>



Radio Habana Cuba